US biopharma firm AbbVie and Allergan Aesthetics, the maker of Botox, will jointly present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) annual meeting, in Boston. AbbVie said that the presentations would underline latest developments in their research including that on the efficacy,  durability and safety of RINVOQ (upadacitinib) and SKYRIZI (risankizumab-rzaa). Allergan aesthetics have revealed that the company will elaborate on its novel hydrating serum in addition to  hyaluronic acid (HA) injectable gel for jawline definition and onabotulinumtoxin A for the treatment of masseter muscle prominence.